Trial Profile
A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 May 2014
Price :
$35
*
At a glance
- Drugs Omega-3 carboxylic acids (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms EPIC-2
- Sponsors Tillotts Pharma
- 27 May 2014 New trial record
- 19 Oct 2005